The hepatic expression of FXR was reciprocally changed to NLRP3 components and interleuckin-1β as a key product of the inflammasome activation in patients with liver disease including NAFLD [84]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.